Truist Securities on Insmed (INSM): brensocatib in HS failure unsuprising, 'stock doesn't reflect any meaningful value for HS'
Truist Securities analyst Danielle Brill reiterated a Buy rating and $205.00 price target on Insmed (NASDAQ: INSM)The analyst commented, "Insmed ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)